Drugs / SPEEDA
SPEEDA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05549908 | Jul 2020 → Oct 2021 | rabies | Changchun Zhuoyi Biological Co., Ltd | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT01827917 | Feb → Dec 2013 | — | Beijing Center for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT01821911 | Jul 2012 → Dec 2013 | blood group incompatibility | Beijing Center for Disease Control and Prevention | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01603875 | Jul 2012 → Jul 2013 | — | Queen Saovabha Memorial Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01137045 Comparator | Jun 2010 → Apr 2018 | rabies | Queen Saovabha Memorial Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPEEDA | “Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.” PMID 28121231 ↗ Jan 20173“new Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA®)” NCT01603875 ↗ “Inoculate SPEEDA® according to 2-1-1 immunization procedure” NCT05549908 ↗ |
| Known as | purified vero cell cultured rabies vaccine | “Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.” PMID 28121231 ↗ Jan 2017 |
| Known as | Speeda Rabies Vaccine | “The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use” NCT01821911 ↗ |
| Modality | Vaccine | “Purified Vero-cell Rabies Vaccine(SPEEDA®)” NCT01603875 ↗ |
| Route | Other | “will be given at each of two sites,intradermally on upper arms” NCT01137045 ↗ |